Allegra Orthopaedics Limited designs, sells, and distributes medical device products in Australia and New Zealand.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.23|
|52 Week High||AU$0.13|
|52 Week Low||AU$0.65|
|1 Month Change||-6.00%|
|3 Month Change||17.50%|
|1 Year Change||67.86%|
|3 Year Change||38.24%|
|5 Year Change||161.11%|
|Change since IPO||-58.04%|
Recent News & Updates
What Does Allegra Orthopaedics' (ASX:AMT) CEO Pay Reveal?
This article will reflect on the compensation paid to Jenny Swain who has served as CEO of Allegra Orthopaedics Limited...
We Think Allegra Orthopaedics (ASX:AMT) Can Easily Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|AMT||AU Medical Equipment||AU Market|
Return vs Industry: AMT exceeded the Australian Medical Equipment industry which returned -6.5% over the past year.
Return vs Market: AMT exceeded the Australian Market which returned 20.2% over the past year.
Stable Share Price: AMT is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: AMT's weekly volatility has decreased from 24% to 13% over the past year, but is still higher than 75% of Australian stocks.
About the Company
Allegra Orthopaedics Limited designs, sells, and distributes medical device products in Australia and New Zealand. It operates in two segments, Orthopedics Division and Innovation Division. The company provides adult and adolescent clavicle fixation systems; a range of symmetrical and asymmetrical offsets for shoulder; and StripEase, distal radius systems, compression screws, hand fracture systems, ulna shortening plates, and modular ceramic or CoCr heads for hand and wrist.
Allegra Orthopaedics Fundamentals Summary
|AMT fundamental statistics|
Is AMT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AMT income statement (TTM)|
|Cost of Revenue||AU$1.87m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0055|
|Net Profit Margin||-9.19%|
How did AMT perform over the long term?See historical performance and comparison
Is Allegra Orthopaedics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AMT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate AMT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: AMT is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.
PE vs Market: AMT is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AMT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AMT is overvalued based on its PB Ratio (5.4x) compared to the AU Medical Equipment industry average (5x).
How is Allegra Orthopaedics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Allegra Orthopaedics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Allegra Orthopaedics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AMT is currently unprofitable.
Growing Profit Margin: AMT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AMT is unprofitable, and losses have increased over the past 5 years at a rate of 4.3% per year.
Accelerating Growth: Unable to compare AMT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AMT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).
Return on Equity
High ROE: AMT has a negative Return on Equity (-12.66%), as it is currently unprofitable.
How is Allegra Orthopaedics's financial position?
Financial Position Analysis
Short Term Liabilities: AMT's short term assets (A$4.8M) exceed its short term liabilities (A$1.6M).
Long Term Liabilities: AMT's short term assets (A$4.8M) exceed its long term liabilities (A$165.3K).
Debt to Equity History and Analysis
Debt Level: AMT's debt to equity ratio (6.4%) is considered satisfactory.
Reducing Debt: AMT's debt to equity ratio has reduced from 46.3% to 6.4% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AMT has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: AMT has less than a year of cash runway if free cash flow continues to reduce at historical rates of 7.5% each year
What is Allegra Orthopaedics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AMT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AMT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AMT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AMT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AMT's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ms. Jenny Swain has been the Chief Executive Officer of Allegra Orthopaedics Limited since May 2, 2016. Ms. Swain served as Director Sales and Marketing of Allegra Orthopaedics Limited and served as its Na...
CEO Compensation Analysis
Compensation vs Market: Jenny's total compensation ($USD285.41K) is about average for companies of similar size in the Australian market ($USD302.06K).
Compensation vs Earnings: Jenny's compensation has been consistent with company performance over the past year.
Experienced Management: AMT's management team is considered experienced (4.8 years average tenure).
Experienced Board: AMT's board of directors are considered experienced (6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Allegra Orthopaedics Limited's employee growth, exchange listings and data sources
- Name: Allegra Orthopaedics Limited
- Ticker: AMT
- Exchange: ASX
- Founded: 1994
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$24.548m
- Shares outstanding: 104.46m
- Website: https://www.allegraorthopaedics.com
- Allegra Orthopaedics Limited
- 18-20 Orion Road
- Level 8
- Lane Cove West
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/20 07:02|
|End of Day Share Price||2021/10/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.